文献速递妇科

子宫内膜癌ProMisE分子亚组中DNA倍体的评估

Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2017-06-21

研究对90例子宫内膜癌病例用图像细胞术评估DNA倍体,并与ProMisE分子亚组及临床病理参数关联。异常DNA倍体在p53 abn组占80.9%(17/21),p53 wt组37.0%(10/27),POLE EDM组28.6%(4/14),MMR-D组14.3%(4/28),组间差异p<0.001。异常DNA含量与更差无进展生存期相关(p=0.0094),在MMR-D组内与更差总生存期(p=0.041)和无进展生存期(p=0.011)相关,作者认为值得进一步研究。

要点

  • 异常DNA倍体在p53 abn组占80.9%(17/21),p53 wt组37.0%(10/27),POLE EDM组28.6%(4/14),MMR-D组14.3%(4/28),组间差异p<0.001。
  • 全队列中异常DNA含量与更差无进展生存期相关(p=0.0094),与疾病特异性生存期(p=0.249)和总生存期(p=0.187)无显著相关。
  • MMR-D组内异常DNA含量与更差总生存期(p=0.041)和无进展生存期(p=0.011)相关,其余3组未见统计学显著关系。

核心结论

  • 异常DNA倍体状态与子宫内膜癌ProMisE分子亚组相关,p53 abn组绝大多数病例可见异常DNA含量。
  • 异常DNA倍体也见于p53 wt、POLE EDM和MMR-D组,但例数较少,因此异常DNA含量并非任何单一分子组的特异性标志物。
  • 将倍体加入ProMisE分子分类可在MMR-D组内提供额外预后价值,值得进一步研究。

研究设计与样本

  • 对90例既往已按临床病理参数、结局和ProMisE分子亚组(POLE EDM、MMR-D、p53 wt或p53 abn)分类的子宫内膜癌病例,用图像细胞术评估DNA倍体。
  • 同时检验倍体与传统临床病理参数的关联。

主要发现

  • 异常DNA倍体状态在ProMisE各组间存在差异(p<0.001):p53 abn组80.9%(17/21),p53 wt组37.0%(10/27),POLE EDM组28.6%(4/14),MMR-D组14.3%(4/28)。
  • 异常DNA含量与更低BMI显著相关(p=0.034),与3级肿瘤显著相关(p=0.001)。
  • 全队列中异常DNA含量与更差无进展生存期显著相关(p=0.0094),与疾病特异性生存期(p=0.249)和总生存期(p=0.187)无显著相关。
  • MMR-D组内异常DNA含量与更差总生存期(p=0.041)和无进展生存期(p=0.011)相关;其余3组未见统计学显著关系。

临床怎么用

  • 作者认为将倍体加入ProMisE分子分类可在MMR-D组内提供额外预后价值,值得进一步研究。

局限性

  • 原文报告「merits further study」,即需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to determine whether DNA ploidy correlates with the four molecular subgroups of endometrial carcinoma (EC) as determined using ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). METHODS: 90 cases of EC previously characterized by clinicopathological parameters, outcomes, and ProMisE molecular subgroup (POLE EDM, MMR-D, p53 wt or p53 abn) were assessed for DNA ploidy using image cytometry. Associations of ploidy with traditional clinicopathological parameters were also tested. RESULTS: Abnormal DNA ploidy status differed amongst the ProMisE groups (p<0.001) and was found in 80.9% (17/21) of p53 abn, 37.0% (10/27) of p53 wt, 28.6% (4/14) of POLE EDM and 14.3% (4/28) of MMR-D. Abnormal DNA content was significantly associated with lower BMI (p=0.034) and grade 3 tumors (p=0.001). In the entire cohort, abnormal DNA content was significantly associated with worse progression free survival (p=0.0094) but not disease specific survival (p=0.249) or overall survival (p=0.187). When examining ploidy within each of the ProMisE groups, abnormal DNA content correlated with worse overall survival (p=0.041) and progression free survival (p=0.011) in the MMR-D group. No statistically significant relationship was seen in the remaining 3 groups. CONCLUSION: Abnormal DNA ploidy status did correlate with the molecular subgroups of EC; abnormal DNA content was seen in the large majority of p53 abn cases. Abnormal ploidy however was also seen in smaller numbers in the p53 wt, POLE EDM and MMR-D groups; therefore abnormal DNA content was not a specific marker for any one molecular group. The addition of ploidy to the ProMisE molecular categories conferred additional prognostic value within the MMR-D group, which merits further study.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Proctor L, Pradhan M, Leung S, et al. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer. Gynecol Oncol. 2017. PMID: 28647100. doi:10.1016/j.ygyno.2017.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。